Home|Journals|Articles by Year Follow on Twitter

Directory for Medical Articles
 

Open Access

Original Article

J App Pharm Sci. 2021; 11(7): 132-145


Phytochemical screening and in silico pharmacological profiling of ethanolic extract of Aframomum melegueta for prostate carcinoma

Asiat NaAllah, Yusuf Oloruntoyin Ayipo, Damilola Ibukun Komolafe, Sobiat Solihu, Bukola Bamidele, Mutiu Adewunmi Alabi, Abdul-Azeez Balogun, Azeemat Titilola Abdulazeez, Mohd Nizam Mordi.

Abstract
Prostate remains the most common cancer in men and among the leading causes of cancer-related deaths worldwide. However, incessant resistance by the disease, inadequate effective prevention and treatment strategies, and affordability are major challenges in curtailing its threat. This study is aimed at the identification of potential antiprostate phytochemicals in ethanolic extract of Aframomum melegueta, acting through a “one-drug-multipletarget” approach using a network of computational tools. Using glide docking simulations, the inhibitory potentials of the phytoconstituents were evaluated against three receptors relevant to prostate therapy: the human androgen receptor from protein data bank (PDB 5T8E), cyclooxygenase-2 (PDB 4PH9), and cytochrome P450 17A1 (PDB 3RUK). The bioactivity, physicochemical, and toxicological profiles, and mutagenicity of the selected phytochemicals were predicted in silico using Prediction of Activity Spectra for Substances online, SwissADME, and VEGA ToxRead tools. From molecular docking, the phytochemicals, caryophyllene, humulene, 5α-androstan-16-one, [1,3] benzodioxolo[5,6-c]phenanthridine, and d-norandrostane (5α;14α) possess a good binding affinity for each receptor in similarity with the co-crystallized ligands and mostly in higher terms than the reference drugs. They are strongly predicted as antineoplastic, apoptosis agonists, CYP2J substrates, NADP+ inhibitors, and agents for prostate disorder. They demonstrate interesting drug-like profiles with a low expression for toxicity and mutagenicity. The easily accessible phytochemicals are promising potentials, amenable for translational designs into effective antiprostate therapeutics upon further study.

Key words: Aframomum melegueta, prostate cancer, molecular docking, mutagenicity, ADMET, drug discovery



Similar Articles

Disparities in Genetic Testing for Heritable Solid-Tumor Malignancies.
Dillon J, Ademuyiwa FO, Barrett M, Moss HA, Wignall E, Menendez C, Hughes KS, Plichta JK
Surgical oncology clinics of North America. 2022; 31(1): 109-126

Financial Toxicity and Shared Decision Making in Oncology.
Greenup RA
Surgical oncology clinics of North America. 2022; 31(1): 1-7

Epsin 3 potentiates the NF‑κB signaling pathway to regulate apoptosis in breast cancer.
Wu Q, Li Q, Zhu W, Zhang X, Li H
Molecular medicine reports. 2022; 25(1):

Construction of a sensitive and selective plasmonic biosensor for prostate specific antigen by combining magnetic molecularly-imprinted polymer and surface-enhanced Raman spectroscopy.
Turan E, Zengin A, Suludere Z, Kalkan NĂ–, Tamer U
Talanta. 2022; 237(): 122926

Organelle-inspired supramolecular nanomedicine to precisely abolish liver tumor growth and metastasis.
Zhan J, Wang Y, Ma S, Qin Q, Wang L, Cai Y, Yang Z
Bioactive materials. 2022; 9(): 120-133


Full-text options


Latest Statistics about COVID-19
• pubstat.org


Add your Article(s) to Indexes
• citeindex.org






Covid-19 Trends and Statistics
ScopeMed.com
CiteIndex.org
CancerLine
FoodsLine
PhytoMedline
Follow ScopeMed on Twitter
Author Tools
eJPort Journal Hosting
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
ScopeMed is a Database Service for Scientific Publications. Copyright © ScopeMed® Information Services.



ScopeMed Web Sites